Gland Pharma
Drug Manufacturers - Specialty & Generic · GLAND
Large CapHealthcareHigh Growth
Shyamakant Giri
Chief Executive Officer · Pragmatic
Company DNA
Performance-Driven
About
Gland Pharma is a Large Cap company in the Healthcare sector, listed on NSE as GLAND. With a market cap of ₹28K Cr and revenue of ₹6K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Highly professionalized generic manufacturing environment with strict regulatory and KPI compliance common in specialized healthcare firms. Its strategic mandate: Navigating complex global regulatory environments while expanding into niche generic injectables requires a leader focused on R&D-driven product innovation.
FAQ
What kind of company is Gland Pharma?
Gland Pharma is a Large Cap Healthcare company (GLAND) in the High Growth phase with a market cap of ₹28K Cr. It is classified as Performance-Driven in culture.
What is Gland Pharma's culture and work environment like?
Gland Pharma has a Performance-Driven culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. Highly professionalized generic manufacturing environment with strict regulatory and KPI compliance common in specialized healthcare firms.
Who leads Gland Pharma?
Gland Pharma is led by Shyamakant Giri (Chief Executive Officer), a Pragmatic leader with 28 years of experience.
What are Gland Pharma's financials?
Gland Pharma reported revenue of ₹6K Cr in FY25 with a 5-year revenue CAGR of 8.4%. Operating margin: 15.9%. Market cap: ₹28K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
Highly professionalized generic manufacturing environment with strict regulatory and KPI compliance common in specialized healthcare firms.
Mandate
Navigating complex global regulatory environments while expanding into niche generic injectables requires a leader focused on R&D-driven product innovation.
Navigating complex global regulatory environments while expanding into niche generic injectables requires a leader focused on R&D-driven product innovation.
Financials
Revenue FY25₹6K Cr
PAT FY25₹699 Cr
Rev CAGR 5Y8.4%
OPM15.9%
NPM12.5%
ROE7.6%
ROCE9.2%
P/E31.6
Fwd P/E22.6
P/B2.8
D/E3.2
Mkt Cap₹28K Cr
Promoter51.8%
Institutional36.7%
Similar Culture
Could You Lead Gland Pharma?
Take the Genome Benchmark →